Building upon evidence demonstrating the beneficial impact on cancer treatment outcomes when combining HDACis and RTK pathway inhibitors, clinical translation of these insights is currently being expedited, highlighted by a study that reported the design and synthesis of a novel class of RTK/HDAC dual-targeted inhibitors [61, 67]. The gene discussed is HDAC9; the disease is cancer.